• Genetics in Drug Discovery - Key to Clinical Trial Success?

    Genetics In Drug Discovery: The Key To Clinical Trial Success?

    Article August 28, 2024

    By leveraging human genetics to identify drug targets with a proven link to disease mechanisms, the probability of clinical trial success greatly increases [1].  Only 10% of drugs that enter phase 1 clinical trials eventually make it to market [2], primarily due to issues related to efficacy or safety that arise later on. These frequent […]

  • NLP for Drug Discovery - How DISGENET works

    How DISGENET Uses NLP To Accelerate Drug Development

    Article, Product July 19, 2024

    With DISGENET, you can easily unlock new insights and greatly accelerate your drug development journey. Every year, more than 1 million papers enter PubMed in the biomedical field [1]. While medical knowledge doubles every 73 days and is increasing at an exponential rate with no evidence of slowing [2], drug discovery and development remain a […]

  • Anticipating Drug Toxicity: data-driven drug safety with DISGENET

    Article September 12, 2023

    Key points What is flupirtine? Flupirtine, an aminopyridine introduced in 1984 as a non-opioid analgesic for acute and chronic pain, embarked on a tumultuous journey within the medical landscape. Initially approved for broad pain management, its trajectory shifted in 2013 due to concerns over liver toxicity. The European Medicines Agency (EMA) limited its use to […]

  • Genetics for drug and chemical risk assessment

    Article March 9, 2023

    In recent years, there has been an increasing appreciation of the need to consider variability in human populations in evaluating health risks for new and existing chemicals. Recent policies such as The Frank R. Lautenberg Chemical Safety for the twenty-first Century Act (2016) require the US Environmental Protection Agency to evaluate new and existing toxic chemicals with explicit […]

  • Genetic support for FDA approvals in 2021

    Article October 6, 2022

    Key points Human genetics and FDA drug approvals in 2021 There is compelling evidence of the value of incorporating genetic information in the drug development process. A drug target supported by genetic evidence has a 2-fold higher probability of successful clinical development compared to those targets with no genetic support [1]. A systematic analysis of FDA […]